Are patients with lung cystic fibrosis at increased risk of severe and fatal COVID-19? Interleukin 6 as a predictor of COVID-19 outcomes

Pol Arch Intern Med. 2020 Oct 29;130(10):919-920. doi: 10.20452/pamw.15630. Epub 2020 Oct 5.

Authors

Janusz Marcinkiewicz¹, Henryk Mazurek², Grzegorz Majka³, Benjamin Chain⁴

Affiliations

¹ Chair of Immunology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland. janusz.marcinkiewicz@uj.edu.pl
² Department of Pneumonology and Cystic Fibrosis, Institute of Tuberculosis and Lung Disorders, Rabka-Zdrój, Poland
³ Chair of Immunology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
⁴ Division of Infection and Immunity, University College London, London, United Kingdom

PMID: 33016684
DOI: 10.20452/pamw.15630

No abstract available

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
COVID-19
Coronavirus Infections*
Coronavirus*
Cystic Fibrosis*
Humans
Immune System
Interleukin-6
Pandemics*
Pneumonia, Viral*
SARS-CoV-2

Substances

Interleukin-6